Innate Pharma Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jonathan Dickinson
Algemeen directeur
€939.6k
Totale compensatie
| Percentage CEO-salaris | 58.53% |
| Dienstverband CEO | 1.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2.7yrs |
| Gemiddelde ambtstermijn bestuur | 1.3yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Aug 11
IPH: Sobi Partnership And 2026 Oncology Readouts Will Reframe Risk Reward Profile
Analysts have raised their fair value estimate for Innate Pharma from €4.50 to €5.60, citing recent price target increases related to the lacutamab partnership with Sobi and renewed interest in wholly owned IPH4502. Analyst Commentary Recent Street research on Innate Pharma has highlighted both supportive and cautious viewpoints as investors weigh the implications of the lacutamab partnership with Sobi and the focus on IPH4502.
Narratiefupdate • Jun 26
IPH: 2026 Lung Cancer Trial Data Will Support Higher Future Multiple
Analysts have trimmed their fair value estimate for Innate Pharma from €6.10 to €5.35, citing updated assumptions that combine higher revenue growth expectations with a much lower profit margin outlook and a substantially higher future P/E multiple. What’s in the News for Innate Pharma Innate Pharma plans to present interim results from the Phase 2 MATISSE trial of IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non small cell lung cancer at the AACR Annual Meeting 2026 in San Diego, California, during a Clinical Trials Plenary Session.Narratiefupdate • Jun 04
IPH: 2026 Oncology Readouts Will Drive Reassessment Of Risk Reward Profile
Analysts have adjusted their price target on Innate Pharma to €8, reflecting updated assumptions on discount rates, revenue growth, profit margins and a very large forward P/E multiple, supported by upcoming oncology catalysts highlighted in recent research. What's in the News Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in resectable non small cell lung cancer are scheduled for a Clinical Trials Plenary Session at the AACR Annual Meeting 2026 in San Diego, California, with abstract code CT231 and session CTPL04, Advances in Immunotherapy, on Tuesday, April 21, 2026, from 10:45 to 11:00 AM PDT.Narratiefupdate • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.Narratiefupdate • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.Narratiefupdate • Apr 09
IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.Analyse-artikel • Mar 29
Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...Narratiefupdate • Mar 25
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.Narratiefupdate • Mar 11
IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.Narratiefupdate • Feb 25
IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.Narratiefupdate • Feb 11
IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.Narratiefupdate • Jan 27
IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).Narratiefupdate • Jan 12
IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.Analyse-artikel • Nov 17
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narratiefupdate • Sep 18
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.Analyse-artikel • Jul 19
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Innate Pharma S.A. ( EPA:IPH ) is a stock to avoid...
Nieuw narratief • Apr 04
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.Analyse-artikel • Apr 02
News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Celebrations may be in order for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Analyse-artikel • Feb 22
Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Innate Pharma S.A. ( EPA:IPH ) shares have continued their recent momentum with a 26% gain in the last month alone. The...Analyse-artikel • Dec 20
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Innate Pharma S.A. ( EPA:IPH ) shares have had a really impressive month, gaining 37% after a shaky period beforehand...Analyse-artikel • Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
It's not a stretch to say that Innate Pharma S.A.'s ( EPA:IPH ) price-to-sales (or "P/S") ratio of 4.1x right now seems...Analyse-artikel • May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 3.4x Innate Pharma S.A. ( EPA:IPH ) is definitely a stock...Analyse-artikel • Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Innate Pharma S.A. ( EPA:IPH ) just released its latest annual results and things are looking bullish. The results were...Analyse-artikel • Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...Analyse-artikel • Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | €940k | €550k | -€49m |
| Sep 30 2025 | n/a | n/a | -€48m |
| Jun 30 2025 | n/a | n/a | -€46m |
| Mar 31 2025 | n/a | n/a | -€48m |
| Dec 31 2024 | €435k | €92k | -€49m |
Compensatie versus markt: De totale vergoeding ($USD 1.09M ) Jonathan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 559.70K ).
Compensatie versus inkomsten: De vergoeding van Jonathan is gestegen terwijl het bedrijf verliesgevend is.
CEO
Jonathan Dickinson (58 yo)
1.8yrs
Tenure
€939,625
Compensatie
Mr. Jonathan E. Dickinson, MBA, BSc served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. Mr. Dickinson is Chief Executive Officer of Innate P...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | €939.63k | geen gegevens | |
| Executive VP & COO | 2.7yrs | €163.69k | 0.40% € 586.7k | |
| Executive VP & Chief Medical Officer | 1.7yrs | €188.14k | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Senior VP & CFO | 5.4yrs | geen gegevens | 0.080% € 117.8k | |
| Vice President of Investor Relations | 1.7yrs | geen gegevens | 0.031% € 46.4k | |
| VP, Chief of Compliance & Operations Officer and Interim Head of HR | 7.7yrs | geen gegevens | 0.15% € 213.6k | |
| VP of Legal & Corporate Affairs and Secretary of the Supervisory Board | 3.7yrs | geen gegevens | 0.054% € 79.5k |
2.7yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | €939.63k | geen gegevens | |
| Director | 1.3yrs | geen gegevens | geen gegevens | |
| Director | 1.3yrs | €34.00k | geen gegevens | |
| Director | 1.3yrs | €41.50k | geen gegevens | |
| Independent Director | 1.3yrs | €85.00k | 0.0027% € 3.9k | |
| Independent Chairwoman of the Board | 1.3yrs | geen gegevens | 0.027% € 39.4k | |
| Independent Vice Chairperson of the Board | 1.3yrs | €89.50k | 0.0011% € 1.6k | |
| Independent Director | 1.3yrs | €79.00k | 0.00070% € 1.0k | |
| Strategic Advisory Board Member | 2.7yrs | geen gegevens | geen gegevens | |
| Strategic Advisory Board Member | 7.8yrs | geen gegevens | geen gegevens |
1.3yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IPH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/14 07:10 |
| Aandelenkoers aan het einde van de dag | 2026/09/14 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Innate Pharma S.A. wordt gevolgd door 13 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |